Compare Novartis AG (NVS) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Paycom Software Inc — how do they compare? Novartis AG trades at $154.71 (market cap $298.18B), while Paycom Software Inc trades at $211 (market cap $9.62B). The key difference: Novartis AG is far larger — about 31× Paycom Software Inc's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| NVS | PAYC | |
|---|---|---|
Market Cap | $298.18B | $9.62B |
Sector | Health | Technology |
52-Week High | $168.62 | $233.89 |
52-Week Low | $118.55 | $113.59 |
Enterprise Value | $339.50B | $10.41B |
Dividend Yield | 3.02% | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Paycom Software (PAYC) trades at $214.94, down 0.48% on the day, with a bullish technical signal supported by moving averages. The stock exhibits strong fundamentals, including a 22.78% net income margin and consistent earnings beats, most recently with Q2 2026 EPS of $2.78 versus $2.38 expected. Recent news highlights AI-driven demand and raised 2026 guidance, fueling positive sentiment.
Outlook remains favorable due to robust profitability and growth initiatives, though risks include high valuation multiples and competitive pressures. Analyst consensus is mixed with a $219.22 price target, suggesting modest upside potential from current levels amid balanced buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
